Practical aspects of the organization of ethical review of clinical trials in the context of the COVID-19 pandemic

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The COVID-19 pandemic has greatly affected all spheres of life, including biomedical research. The ethical regulation of clinical trials has a long history in international and domestic practice. An efficient infrastructure of international and national legislation has been created. At the same time, there are features of the organization of ethical review of clinical trials that arise under the restrictions associated with COVID-19. Healthcare of all countries is faced with the need to develop new approaches caused by the speed of the spread of the disease, its severe consequences for the life and health of people, the excessive burden on the medical worker, not only physical, but also psychological, including those associated with ethical problems. The purpose of this research was to study and analyze the experience of ethical review of clinical trials in the context of the COVID-19 epidemic, its regulatory framework in international and domestic practice. For high-quality and lawful conduct of clinical trials in Russia in the context of the COVID-19 epidemic, appropriate conditions were created, namely, a vertical base: the central ethical committee of the Ministry of Health of the Russian Federation — local ethical committees based in clinical institutions and research centers. They are provided with sufficient and high-quality legal support in the form of laws of the Russian Federation, country standards and by-laws. The work of local ethics committees is built in accordance with strict ethical international and domestic standards. Standard operating procedures implemented in local ethics committees provide for all the nuances of situations, including those implemented using modern telecommunication technologies and other end-to-end information technologies. Even if many restrictions are imposed, biomedical research must continue, and accordingly, it must be carried out under the strict control and monitoring of research ethics committees. The article presents an overview of legal sources, an analysis of the main approaches in domestic and foreign literature, taking into account historical retrospective.

Full Text

Restricted Access

About the authors

Farida T. Nezhmetdinova

Kazan State Agrarian University

Author for correspondence.
Email: nadgmi@mail.ru
ORCID iD: 0000-0003-2875-128X
SPIN-code: 8441-6943
Scopus Author ID: 55639803900
ResearcherId: F-9660-2014

Candi. Sci. (Philosoph.), Assoc. Prof., Head of Depart., Depart. of philosophy and law

Russian Federation, Kazan, Russia

Marina E. Guryleva

Kazan State Medical University

Email: meg4478@mail.ru
ORCID iD: 0000-0003-2772-129X

M.D., D. Sci. (Med.), Prof., Depart. of bioethics and health law from the course of history of medicine

Russian Federation, Kazan, Russia

References

  1. Nuremberg Code (1947). Human rights and freedoms in psychiatry. http://www.consultant.ru/law/podborki/nyurnbergskij_kodeks/ (access date: 15.02.2022). (In Russ.)
  2. Declaration of Helsinki of the World Medical Association “Ethical Principles for Medical Research Involving Human Subjects”. http://www.bioethics.ru/ (access date: 15.02.2022). (In Russ.)
  3. ICH GCP — ICH harmonised guideline integra¬ted addendum to ICH E6(R1). Guideline for Good Clinical Practice ICH E6(R2) ICH Consensus Guideline — ICH GCP. https://www.ema.europa.eu/ (access date: 15.02.2022).
  4. Model law on the protection of human rights and dignity in biomedical research. Inter-Parliamentary Assembly of the Confederation of Independent States (Eastern Europe & Central Asia); 2004. http://biomed.nas.gov.ua/files/model_law_eng.pdf (access date: 10.02.2022).
  5. Universal declaration on bioethics and human rights. UNESCO; 2005. https://www.un.org/ru/documents/decl_conv/declarations/bioethics_and_hr.shtml (access date: 15.02.2022).
  6. World Health Organization. Guidance for managing ethical issues in infectious disease outbreaks. 2016. https://apps.who.int/iris/bitstream/handle/10665/250580/9789241549837-eng.pdf?sequence=1&isAllowed=y (access date: 12.02.2022).
  7. Kundiiev YuI, Vitte PN, Chashchin N, Mishatkina T, Sarymsakova B. Developing National Systems for Ethical review in Eastern Europe and Central Asia: Legitimacy and responsibility. Pharmaceutical Medicine. 2008;22(5):285–287. doi: 10.1007/BF03256717.
  8. Sarymsakova BE, Koykov VV, Sausakova SB. Poryadok provedeniya sertifikatsii lokal'nykh komissiy po bioetike. (The procedure for certification of local commissions on bioethics.) Nur-Sultan; 2019. 16 р. (In Russ.)
  9. Karakushikova AS, Mustafina AR, Kudaybergenova A, Shayakhmetov SS. Research Ethics Capacity Building for Ethical Regulation of Research as Important Condition for Transition of University into Research University in Kazakhstan. Izvestiya Natsional'noy akademii nauk Respubliki Kazakhstan. Seriya Biologi¬cheskaya i meditsinskaya. 2012;(5):57–65. (In Russ.)
  10. Dobrova VYe, Zupanets KО, Kolodyezna TY, Timchenko YV. Electronic informed consent model deve¬lopment for implementation in clinical trials in Ukraine. Asian Journal of Pharmaceutical and Clinical Research. 2017;10(12):238–241. doi: 10.22159/ajpcr.2017.v10i12.21044.
  11. Zupanets IA, Dobrova VYe, Ratushna KL, Silchenko SO. Introduction of open visiting policy in intensive care units in Ukraine: Policy analysis and the ethical perspective. Asian Bioeth Rev. 2018;10:105–121. doi: 10.1007/s41649-018-0057-9.
  12. Bioetika i sovremennye problemy meditsinskoy etiki i ¬deontologii: materialy Respublikanskoy nauchno-prakti¬cheskoy konferentsii s mezhdunarodnym uchastiem (Vitebsk, 2 dekabrya 2016 g.). (Bioethics and modern problems of medical ethics and deontology: materials of the Republican scientific and practical conference with international participation (Vitebsk, December 2, 2016).) Ministry of Health of the Republic of Bela¬rus, EE “Vitebsk State Order of Friendship of Peoples Me¬dical University”. Vitebsk: VSMU; 2016. 289 р. (In Russ.)
  13. Zagorodnikova K, Burbello A, Sychev D, Frolov M, Kukes V, Petrov V. Clinical pharmacology in Russia — historical development and current state. Eur J Clin Pharmacol. 2015;71:159–163. doi: 10.1007/s00228-014-1787-6.
  14. Guryleva ME, Nezhmetdinova FT. Introduction of ethical standards into the practice of cli¬nical trials in the Russian Federation through the system of ethical committees. Meditsinskaya antropologiya i bioetika. 2011;(2):11. (In Russ.)
  15. National standard of the Russian Federation GOST R 52379-2005 “Good clinical practice” (approved by order of the Federal Agency for Technical Regulation and Metrology dated September 7, 2005 No. 232-st). https://base.garant.ru/ (access date: 15.02.2022). (In Russ.)
  16. Nezhmetdinova FT, Guryleva ME. Russian school of bioethics: a quarter of a century of development. Kazan Medical Journal. 2018;99(3):521–527. (In Russ.) doi: 10.17816/KMJ2018-521.
  17. Nezhmetdinova FT, Guryleva ME. Medical, social and ethical issues related to COVID-19. Kazan Medical Journal. 2020;101(6):841–851. (In Russ.) doi: 10.17816/KMJ2020-841.
  18. Fede¬ral Law of November 21, 2011 No. 323-FZ “On the Fundamentals of Protecting the Health of Citizens in the Russian Fe¬deration” (with amendments and additions). https://base.garant.ru/ (access date: 08.02.2022). (In Russ.)
  19. Federal Law of April 12, 2010 No. 61-FZ “On the Circulation of Medicines” (with amendments and additions). https://base.garant.ru/ (access date: 08.02.2022). (In Russ.)
  20. Order of the Ministry of Health of the Russian Federation da¬ted November 29, 2012 No. 986n “On Approval of the Re¬gulations on the Ethics Council” (as amended). https://base.garant.ru/ (access date: 15.02.2022). (In Russ.)
  21. Order of the Mi¬nistry of Health of the Russian Federation dated July 10, 2015 No. 435n “On the Ethics Committee of the Ministry of Health of the Russian Federation” (as amended). https://base.garant.ru/ (access date: 15.02.2022). (In Russ.)
  22. Order of the Ministry of Health of the Russian Federation dated April 1, 2016 No. 200n “On approval of the rules of good clinical practice”. https://base.garant.ru/ (access date: 15.02.2022). (In Russ.)
  23. Order of the Ministry of Health of the Russian Federation dated June 19, 2003 No. 266 “On Approval of the Rules for Clinical Practice in the Russian Federation” (lost force). https://base.garant.ru/ (access date: 15.02.2022). (In Russ.)
  24. Clinical Research Portal. https://clinicaltrials.gov (access date: 15.02.2022). (In Russ.)
  25. Atlant Clinical. https://www.atlantclinical.com/ (access date: 15.02.2022).
  26. Kamenskiy A. Trial charm. ¬VADEMECUM. 2016;(14):12–29. (In Russ.)
  27. Clinical trials market size, share, growth, analysis report, 2018–2025. (2018). Grand View Research. https://www.precedenceresearch.com/clinical-trials-market (access date: 12.12.2021).
  28. RosMinzdrav, official site. http://grls.rosminzdrav.ru/ (access date: 18.02.2022). (In Russ.)
  29. Association of Clinical Research Organizations. http://acto-russia.org/ (access date: 15.02.2022). (In Russ.)
  30. Zvonareva L, Kutishenko N, Kulikov E, Martse¬vich S. Risks and benefits of trial participation: A qualitative study of participants’ perspectives in Russia. Clin Trials. 2015;12:646–653. doi: 10.1177/1740774515589592.
  31. Letter of the Ministry of Health of the Russian Federation dated March 27, 2020 No. 20-1/I/2-3651 “On the conduct of clinical trials of drugs in the context of the COVID-19 coronavirus pandemic”. https://www.garant.ru/products/ (access date: 15.02.2022). (In Russ.)
  32. Khokhlov AL, Polozova EA, Komissarova VA, Chudova NV, Cyzman LG. Risks associated with the ¬ethical aspects of conducting clinical trials. Kachestvennaya klinicheskaya praktika. 2020;(1):61–68. (In Russ.) doi: 10.37489/2588-0519-2020-1-61-68.
  33. Decree of the Government of the Russian Federation of April 3, 2020 No. 441 “On the peculiarities of the circulation of medicinal products for medical use, which are intended for use in conditions of the threat of the emergence, occurrence and liquidation of an emergency and for the prevention of emergency situations, the prevention and treatment of diseases that pose a danger to others , diseases and injuries resulting from exposure to adverse chemical, biological, radiation factors”. https://www.rosminzdrav.ru/ministry/61/11/po-voprosam--provedeniyaklinicheskih-issledovaniy-lekarstvennyh-preparatov-v-usloviyah-pandemiikoronavirusa-covid-19 (access date: 15.02.2022). (In Russ.)
  34. Guidance on the Management of Clinical Trials during the COVID-19 (Coronavirus) pandemic. Version 1 (20/03/2020). https://www.famhp.be/sites/default/files/content/guidance_on_the_management_of_clinical_trials_during_the_covid-19_coronavirus_pandemic.pdf (access date: 12.12.2021).
  35. OHRP Guidance on COVID-19 (8 April 2020). https://www.hhs.gov/ohrp/regulations-and-policy/guidance/ohrp-guidance-on-covid-19/index.html (access date: 15.02.2022).
  36. World Health Organization. COVID-19 Public Health Emergency of International Concern (PHEIC) Global research and innovation forum: Towards a research roadmap. 12 February 2020. Available at: https://www.who.int/publications/m/item/covid-19-public-health-emergency-of-international-concern-(pheic)-global-research-and-innovation-forum (access date: 13.02.2022)
  37. Central Asia: ICJ calls on Central Asian States to ensure access to justice during the COVID-19 pandemic. https://www.icj.org/wp-content/uploads/2020/07/Central-Asia-Statement-COVID-19-Advocacy-2020-ENG.pdf (access date: 15.02.2022)
  38. Public health emergency situation due to the COVID-19 pandemic relevant ethical aspects. Position of the National Council of Ethics for the Life Sciences. https://rm.coe.int/pos-cnecv-covid-19-en/16809e3569 (access date: 15.02.2022).
  39. Shok NP. Responsible Science and Society: Can Bioethics Influence Clinical Practice? Monitoring of public opinion: economic and social changes journal. 2020;(2):347–364. (In Russ.) doi: 10.14515/monitoring.2020.2.1624.
  40. Kubar OI. Ethical commentary on COVID-19. Russian Journal of Infection and Immunity. 2020;10(2):287–294. (In Russ.) doi: 10.15789/2220-7619-ECO-1447.
  41. Kubar OI, editor. Etika vaktsinatsii (kriteriy nauchnogo i gumanitarnogo proryva). (Ethics of vaccination (criterion of scientific and humanitarian breakthrough).) St. Petersburg: FBUN NIIEM imeni Pastera; 2018. 176 p. (In Russ.)
  42. Nezhmetdinova F. Global challenges and globa¬lization of bioethics. Croat Med J. 2013;54(1):83–85. doi: 10.3325/cmj.2013.54.83.
  43. Henk ten Have, editor. Encyclopedia of global bioethics. Springer; 2016. 3054 p.
  44. Romodanovsky DP, Goryachev DV, Khokhlov AL, Myroshnikov AE, Shitova AM, Eremenko NN. Patient's risk in studies of bioequivalence of highly variable drugs. Medi¬tsinskaya etika. 2018;(1):26–32. (In Russ.)
  45. Crespin S, Bourrel R, Hurault-Delarue C, Lapeyre-Mestre M, Montastruc JL, Damase-Michel C. Drug prescribing before and during pregnancy in south-west France: a retrospective study. Drug Saf. 2011;34(7):595–604. doi: 10.2165/11589170-000000000-00000.
  46. Zagorodnikova KA, Burbello AT, Pokladova MV. Pharmacovigilance of pregnant women — from “talidomid tragedy” to the present. Remedium. 2012;(8):15–22. (In Russ.)
  47. Approved by the state. How American authorities protected consumers from harmful products. https://nplus1.ru/material/2020/03/30/regulatory-science (access date: 12.03.2022). (In Russ.)
  48. United Nations Educational, Scientific, and Cultu¬ral Organization. Distance learning solutions. 2020. https://en.unesco.org/covid19/educationresponse/solutions (access date: 12.02.2022).

© 2022 Eco-Vector




This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies